About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID
Drd2
dopamine receptor D2
MGI:94924
149 phenotypes from 12 alleles in 24 genetic backgrounds
Export: Excel File
Allelic Composition
Genetic Background
Annotated Term Reference
Drd2m1Anu/Drd2m1Anu
C57BL/NCrlAnu-Drd2m1Anu/Anu
no abnormal phenotype detected J:104190
Drd2tm1(IL2RA)Koba/Drd2+
B6.129P2-Drd2tm1(IL2RA)Koba
abnormal locomotor activation J:85929
decreased dopaminergic neuron number J:85929
unidirectional circling J:85929
Drd2tm1.1Mmsh/Drd2tm1.1Mmsh
Gng7tm1(cre)Mmsh/?
involves: C57BL/6N
normal behavior/neurological phenotype J:210178
Drd2tm1.1Mrub/Drd2tm1.1Mrub
Slc6a3tm1.1(cre)Bkmn/Slc6a3+
B6.Cg-Drd2tm1.1Mrub Slc6a3tm1.1(cre)Bkmn
abnormal inhibitory postsynaptic currents J:176167
abnormal operant conditioning behavior J:176167
abnormal single cell response J:176167
abnormal synaptic dopamine release J:176167
decreased physiological sensitivity to xenobiotic J:176167
enhanced behavioral response to cocaine J:176167
hyperactivity J:176167
increased physiological sensitivity to xenobiotic J:176167
induced hyperactivity J:176167
Drd2tm1.1Mrub/Drd2tm1.1Mrub
Tg(Nes-cre)1Kln/?
involves: 129S4/SvJae * C57BL/6 * SJL
abnormal hormone level J:194227
abnormal social/conspecific interaction J:194227
normal behavior/neurological phenotype J:194227
decreased circulating insulin-like growth factor I level J:194227
decreased growth hormone level J:194227
decreased physiological sensitivity to xenobiotic J:194227
decreased somatotroph cell number J:194227
decreased urine major urinary protein level J:194227
normal homeostasis/metabolism phenotype J:194227
postnatal growth retardation J:194227
slow postnatal weight gain J:194227
Drd2tm1.1Mrub/Drd2tm1.1Mrub
Tg(Prl-cre)1Mrub/?
involves: 129S4/SvJae * C57BL/6 * CBA
decreased physiological sensitivity to xenobiotic J:194227
normal growth/size/body region phenotype J:194227
increased circulating prolactin level J:194227
Drd2tm1Ebo/Drd2+
involves: 129S2/SvPas * C57BL/6
abnormal behavior J:96229
catalepsy J:29045
decreased vertical activity J:29045
hypoactivity J:29045, J:96229
Drd2tm1Ebo/Drd2tm1Ebo
B6.129S2-Drd2tm1Ebo
increased susceptibility to neuronal excitotoxicity J:65767
Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
abnormal adrenal gland zona fasciculata morphology J:110599
abnormal adrenal gland zona reticularis morphology J:110599
abnormal behavior J:96229
abnormal estrous cycle J:41857
abnormal estrus J:41857
abnormal gait J:29045
abnormal melanotroph morphology J:110599
abnormal neuron physiology J:65767
abnormal pituitary gland physiology J:110599
adenohypophysis hyperplasia J:41857
adrenal cortical hyperplasia J:110599
akinesia J:29045
normal behavior/neurological phenotype J:111282
bradykinesia J:29045
catalepsy J:29045
decreased body temperature J:29045
decreased body weight J:29045
decreased circulating estrogen level J:41857
decreased circulating growth hormone level J:41857
decreased fluid intake J:29045
decreased food intake J:29045
decreased lactotroph cell size J:41857
decreased somatotroph cell number J:41857
decreased vertical activity J:29045, J:96229
enlarged adrenocortical cells J:110599
enlarged pituitary gland J:41857
hyperpigmentation J:110599
hypersecretion of corticosterone J:110599
hypoactivity J:29045, J:96229
impaired conditioned place preference behavior J:111282
impaired coordination J:29045
increased circulating adrenocorticotropin level J:110599
increased circulating corticosterone level J:110599
increased circulating pituitary hormone level J:110599
increased circulating prolactin level J:41857
increased lactotroph cell number J:41857
increased pituitary adenoma incidence J:41857
increased susceptibility to neuronal excitotoxicity J:65767
increased susceptibility to pharmacologically induced seizures J:65767
increased thyrotroph cell number J:41857
limp posture J:29045
pituitary gland hyperplasia J:41857
pituitary intermediate lobe hyperplasia J:41857, J:110599
prolonged diestrus J:41857
reduced female fertility J:41857
reduced fertility J:29045
small ovary J:29045
small testis J:29045
Drd2tm1Low/Drd2+
129S/Sv-Drd2tm1Low
abnormal locomotor behavior J:47001
Drd2tm1Low/Drd2+
B6.129S2-Drd2tm1Low
abnormal locomotor behavior J:47001
abnormal systemic arterial blood pressure J:103181
ataxia J:50787
normal behavior/neurological phenotype J:50787
decreased vertical activity J:47001
hypoactivity J:50787
impaired behavioral response to alcohol J:50787
increased body weight J:103181
increased mean systemic arterial blood pressure J:103181
increased systemic arterial diastolic blood pressure J:103181
increased systemic arterial systolic blood pressure J:103181
Drd2tm1Low/Drd2+
involves: 129S2/SvPas * C57BL/6J
abnormal locomotor behavior J:47001
increased physiological sensitivity to xenobiotic J:47001
Drd2tm1Low/Drd2tm1Low
129S/Sv-Drd2tm1Low
abnormal locomotor activation J:47001
abnormal locomotor behavior J:47001
Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2tm1Low
abnormal brain development J:127071
abnormal CNS synaptic transmission J:127071
abnormal excitatory postsynaptic currents J:127071
abnormal latent inhibition of conditioning behavior J:90593
abnormal locomotor activation J:47001, J:103181
abnormal locomotor behavior J:47001, J:50787
abnormal operant conditioning behavior J:90593
abnormal prepulse inhibition J:55027
abnormal response to novel odor J:110704
abnormal systemic arterial blood pressure J:103181
absent long term depression J:127071
alcohol aversion J:50787
ataxia J:50787
normal behavior/neurological phenotype J:50787, J:103181, J:110704
decreased alcohol consumption J:50787
decreased body weight J:130701
decreased pulmonary ventilation J:130701
decreased startle reflex J:154428
decreased vertical activity J:47001
hypoactivity J:50787
impaired behavioral response to addictive substance J:55027
impaired behavioral response to alcohol J:50787
impaired coordination J:47001
increased heart rate J:103181
increased mean systemic arterial blood pressure J:103181
increased physiological sensitivity to xenobiotic J:103181
increased pulmonary respiratory rate J:130701
increased pulmonary ventilation J:130701
increased systemic arterial diastolic blood pressure J:103181
increased systemic arterial systolic blood pressure J:103181
increased tidal volume J:130701
increased urine sodium level J:103181
polyuria J:103181
normal taste/olfaction phenotype J:110704
Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2tm1Low/J
abnormal astrocyte physiology J:194407
abnormal GABAergic neuron morphology J:121219
abnormal neuronal migration J:121219
abnormal vocalization J:134260
astrocytosis J:194407
decreased body length J:106832
decreased body weight J:106832
decreased circulating growth hormone level J:106832
decreased circulating insulin-like growth factor I level J:106832
decreased inguinal fat pad weight J:106832
decreased liver weight J:106832
decreased physiological sensitivity to xenobiotic J:137069
decreased response to stress-induced hyperthermia J:137069
decreased sensitivity to xenobiotic induced morbidity/mortality J:137069
decreased spleen weight J:106832
increased circulating prolactin level J:106832
increased food intake J:106832
increased growth hormone level J:106832
increased interleukin-1 beta secretion J:194407
increased susceptibility to dopaminergic neuron neurotoxicity J:194407
microgliosis J:194407
normal nervous system phenotype J:194407
postnatal growth retardation J:106832
short femur J:106832
Drd2tm1Low/Drd2tm1Low
either: B6.129S2-Drd2tm1Low or (involves: 129S2/SvPas * C57BL/6)
abnormal adenohypophysis morphology J:41858
abnormal pituitary gland morphology J:41858
adenohypophysis hyperplasia J:41858
adenohypophysis hypertrophy J:41858
adenohypophysis peliosis J:41858
decreased gonadotroph cell number J:41858
decreased physiological sensitivity to xenobiotic J:41858
enlarged pituitary gland J:41858
increased circulating prolactin level J:41858
increased lactotroph cell number J:41858
increased pituitary gland weight J:41858
short uterine horn J:41858
uterus adenomyosis J:41858
uterus cysts J:41858
uterus hyperplasia J:41858
Drd2tm1Low/Drd2tm1Low
involves: 129 * C57BL/6
abnormal locomotor activation J:102700
Drd2tm1Low/Drd2tm1Low
involves: 129S2/SvPas * C57BL/6J
abnormal locomotor activation J:47001
abnormal locomotor behavior J:47001
decreased physiological sensitivity to xenobiotic J:47001
decreased vertical activity J:47001
Drd2tm1Mok/Drd2tm1Mok
involves: 129S/SvEv
abnormal single cell response J:97412
Drd2tm1Mok/Drd2tm1Mok
involves: 129S/SvEv * C57BL/6J * DBA/2J
abnormal circulating hormone level J:97838
abnormal single cell response J:97838
darkened coat color J:97838
enlarged pituitary intermediate lobe J:97838
increased pituitary hormone level J:97838
Drd2tm1Schm/Drd2tm1Schm
B6.Cg-Drd2tm1Schm
abnormal intestinal absorption J:106280
abnormal intestinal transit time J:106280
abnormal large intestinal transit time J:106280
decreased body weight J:106280
increased defecation amount J:106280
increased fluid intake J:106280
increased food intake J:106280
Drd2tm1Schm/Drd2tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
abnormal dopamine level J:79483
abnormal locomotor behavior J:79483
bradykinesia J:79483
decreased body size J:79483
decreased body weight J:79483
hunched posture J:79483
premature death J:79483
Drd2tm1Srcmo/Drd2tm1Srcmo
Tg(GFAP-cre)25Mes/0
involves: C57BL/6 * FVB/N
abnormal astrocyte physiology J:194407
astrocytosis J:194407
normal nervous system phenotype J:194407
Drd2tm1Yyw/Drd2+
B6.129S4-Drd2tm1Yyw
abnormal behavioral response to xenobiotic J:82829
Drd2tm1Yyw/Drd2tm1Yyw
B6.129S4-Drd2tm1Yyw
abnormal behavioral response to xenobiotic J:65770, J:82829
decreased anxiety-related response J:65770
decreased vertical activity J:65770
hypoactivity J:65770
Drd2tm1Yyw/Drd2tm1Yyw
involves: 129S4/SvJae * C57BL/6
bradykinesia J:65770
decreased anxiety-related response J:65770
decreased vertical activity J:65770
hypoactivity J:65770
impaired behavioral response to xenobiotic J:65770
Drd2tm1Yyw/Drd2tm1Yyw
involves: 129S4/SvJae * C57BL/6J
decreased aggression towards males J:103562
Drd2tm2Ebo/Drd2tm2Ebo
involves: 129S2/SvPas * C57BL/6
normal behavior/neurological phenotype J:77277
enhanced behavioral response to xenobiotic J:77277
impaired behavioral response to xenobiotic J:77277
Drd2tm3.1Ebo/Drd2tm3.1Ebo
En1tm2(cre)Wrst/En1+
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6
abnormal dopamine level J:185643
abnormal nervous system electrophysiology J:185643
decreased physiological sensitivity to xenobiotic J:185643
enhanced behavioral response to anesthetic J:185643
enhanced behavioral response to cocaine J:185643
enhanced behavioral response to xenobiotic J:185643
hyperactivity J:185643
increased dopamine level J:185643
increased vertical activity J:185643
induced hyperactivity J:185643
Drd2tm3.1Ebo/Drd2tm3.1Ebo
Tg(Drd1a-cre)AGsc/0
involves: 129S2/SvPas * C57BL/6 * FVB/N
abnormal dopamine level J:185643
abnormal nervous system electrophysiology J:185643
decreased physiological sensitivity to xenobiotic J:185643
hypoactivity J:185643
impaired behavioral response to anesthetic J:185643
impaired behavioral response to cocaine J:185643
impaired coordination J:185643
normal nervous system phenotype J:185643

Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
11/14/2017
MGI 6.11
The Jackson Laboratory